Acromegaly is a rare disorder caused excessive production of Growth Hormone (GH) by pituitary gland, due to this tissues and bones in the body grows more rapidly which may leads to abnormal hands and feet. When acromegaly is caused before puberty it is called Gigantism. Early symptoms of Acromegaly includes swollen hands and feet, sleep apnea, difficulty in sleeping, numbness and weakness in hands, changes in skin, etc. Acromegaly can be diagnosed by brain scans and blood tests like IGF test, Glucose Tolerance test. Acromegaly can be treated by surgery, radiation therapy, and medications like Somatostatin analogs, GH receptor antagonists and Dopamine agonists.
Key Developments:
Latin America
Europe
Asia Pacific
Middle East
North America
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Acromegaly Disease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Acromegaly Disease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Acromegaly Disease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Drugs |
| 2.2.2. Route of Administration |
| 3. Global Acromegaly Disease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Acromegaly Disease Pipeline Drugs Assessment Market Analysis, 2019 -2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Acromegaly Disease Pipeline Drugs Assessment Market By Drugs, 2019 -2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Octreotide |
| 5.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Pasireotide |
| 5.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Lanreotide |
| 5.3.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Sandostatin |
| 5.4.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Somatuline |
| 5.5.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Pegvisomant |
| 5.6.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6. Global Acromegaly Disease Pipeline Drugs Assessment Market By Route of Administration, 2019 -2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2019 -2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Competition Landscape |
| 7.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 7.2.1.Novartis |
| 7.2.2.Italfarmaco |
| 7.2.3.Chiasma, Inc. |
| 7.2.4.Ipsen |
| 7.2.5.Endo Pharmaceuticals |
| 7.2.6.Pfizer |
| 7.2.7.AmbriliaBiopharma, Inc. |
| 8. Research Methodology |
| 9. Appendix and Abbreviations |